Research from Johns Hopkins Kimmel Cancer Center experts revealed a type of RNA, previously considered to be "junk," that may help doctors distinguish and treat a subgroup of patients with medulloblastoma.
Mar 23, 2023
0
27
An international team led by the Department of Neurosurgery, Niigata University, has identified a new gene called Schlafen11 (SLFN11) whose expression is tightly correlated with the response to chemotherapy in medulloblastomas, ...
Nov 8, 2022
0
7
It may soon be possible to identify Group 4 medulloblastomas—the most common malignant brain tumor in children—from more aggressive Group 3 tumors. Research based on a little-explored part of RNA, which creates proteins, ...
Sep 21, 2022
0
3
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial ...
Jul 14, 2022
0
13
Researchers at the University of British Columbia (UBC) and BC Cancer, in partnership with BC Children's Hospital Research Institute (BCCHR), have developed a new test to more easily diagnose medulloblastoma, the most common ...
Nov 1, 2021
0
12
(HealthDay)—For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology.
Jul 23, 2021
0
1
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
May 20, 2021
0
7
Johns Hopkins researchers have discovered a new diagnostic marker that distinguishes a fast-growing type of the pediatric brain cancer medulloblastoma from a less aggressive type. The researchers hope that this biomarker ...
Dec 10, 2020
0
7
Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children's Cancer Center Heidelberg (KiTZ) have demonstrated that personalized drug screens ...
Nov 12, 2020
0
13
Investigators at St. Jude Children's Research Hospital have found that the ABCC4 transporter is critical to the SHH signaling pathway in the brain tumor medulloblastoma. This work provides a rationale for development of small ...
Mar 31, 2020
0
0
